Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to AML
Related studies linked through entity extraction aliases.
Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.
- Status
- NOT_YET_RECRUITING
- Phase
- NA
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- Status
- RECRUITING
- Phase
- PHASE1
Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML
- Status
- NOT_YET_RECRUITING
- Phase
- NA
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
- Status
- RECRUITING
- Phase
- PHASE1
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
- Status
- RECRUITING
- Phase
- PHASE2
Relation of C-reactive Protein/ Albumin Ratio and Coagulation Profile in Acute Myeloid Leukemia Patients
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
- Status
- RECRUITING
- Phase
- NA
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
- Status
- ENROLLING_BY_INVITATION
- Phase
- EARLY_PHASE1
Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- NA